The findings suggest that FOSL1 has a role in promoting cancer growth via AKT and enhancing cancer cell migration through JNK/c-Jun, identifying FOSL1 as a significant integrator of JNK and AKT signaling pathways, and a promising therapeutic target for treating cSCC and HNSCC [103]. This evidence concerns the gene MAPK8 and skin squamous cell carcinoma.